Ignite Creation Date:
2024-05-06 @ 8:17 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06321523
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-17
First Post:
2024-03-13
Brief Title:
A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy ATTR-CM
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Clinical Benefit of Tafamidis 61mg for Transthyretin Amyloid Cardiomyopathy ATTR-CM Patients in Korean Population in the Real-world Setting Multicenter Non-interventional Study
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this clinical trial is to learn about the effects of the study medicine called Tafamidis 61milligrams mg for the potential treatment of Transthyretin amyloid cardiomyopathy ATTR-CM
This study is seeking participants who were prescribed Tafamidis 61mg after being diagnosed with ATTR-CM and have taken Tafamidis 61mg at least once
We will examine the experiences of people receiving the study medicine This will help us determine if the study medicine is safe and effective
This study is seeking participants who were prescribed Tafamidis 61mg after being diagnosed with ATTR-CM and have taken Tafamidis 61mg at least once
We will examine the experiences of people receiving the study medicine This will help us determine if the study medicine is safe and effective
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None